Announcements Trials
Browse Landscape

Phase

Phase 1 8Phase 2 2Phase EARLY_PHASE1 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 206Lymphoid 165Other hematologic neoplasm 75Myeloid 12Genitourinary 7Dermatologic 6Sarcoma 4Gastrointestinal 4Classical hematology 3CNS 2Thoracic 1Head & Neck 1

Conditions

Optic Nerve Glioma 1Neurofibromatosis 1 1Gliosarcoma 1Glioma 1Glioblastoma 1Astrocytoma 1

Interventions

Temozolomide 258Radiotherapy 147Bevacizumab 141Etoposide 68Cyclophosphamide 68Carboplatin 66Magnetic Resonance Spectroscopy 58Irinotecan 53Cisplatin 52Vincristine 45Filgrastim 43pembrolizumab 40Radiosurgery 36Nivolumab 36Radiation 34Topotecan 31Doxorubicin 30Specimen Handling 29sargramostim 28Lomustine 27Erlotinib Hydrochloride 27Peripheral Blood Stem Cell Transplantation 25Carmustine 25Thiotepa 24Everolimus 23Chemotherapy, Adjuvant 23Surgical Procedures, Operative 22Isotretinoin 22Ipilimumab 22Melphalan 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Lenalidomide × CNS × Clear all
NCT01553149 2025-01-07

Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma

National Cancer Institute (NCI)

Phase 2 Completed
75 enrolled 17 charts
CNS

Astrocytoma, Neurofibromatosis 1, Optic Nerve Glioma

NCT00165477 2010-03-10

Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme

Dana-Farber Cancer Institute

Phase 2 Completed
23 enrolled
CNSSarcoma

Glioblastoma, Glioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡